FDA-Drug2026-04-29Not Yet ClassifiedCHEMICAL

Teva Claravis (isotretinoin) 10 mg recalled for elevated tretinoin impurity levels

OTHERNationwide distribution

Return Teva Claravis isotretinoin to your pharmacy

Teva Pharmaceuticals is recalling specific lots of Claravis (isotretinoin) 10 mg capsules because they contain higher-than-allowed levels of tretinoin, a related chemical impurity. The affected lots are 100067507 and 100067508, which expire on July 31, 2026. No injuries have been reported so far.

  • Check if you have Claravis 10 mg with lot number 100067507 or 100067508
  • Contact your pharmacy or healthcare provider for instructions on returning the medication
  • Do not stop taking your isotretinoin without speaking to your doctor first—they can provide a safe alternative
Hazard

Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin

Sold states
Nationwide in the USA; Virgin Islands
Affected count
5,101 cartons
Manufactured in
400 Interpace Pkwy Bldg A, N/A, Parsippany, NJ, United States
Products
Claravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, NDC 0555-1054-56, with 10x10 blister packs NDC 0555-1054-60; b) 30-count carton, NDC 0555-1054-86, with 3X10 blister pack NDC 0555-1054-60; Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=98730

More Teva Pharmaceuticals USA, Inc recalls

Don't want to check this manually?

We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Get the Sunday Brief